Skin Toxicities Induced by Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors and their Influence on Treatment Adjustments in Lung Cancer Patients
DOI:
https://doi.org/10.2340/actadv.v104.40555Keywords:
Epidermal growth factor receptor tyrosine kinase inhibitors, Skin toxicities, Dermatological adverse events, Papulopusutlar rash, Xerosis, Paronychia, PruritusAbstract
Skin toxicities caused by epidermal growth factor receptor tyrosine kinase inhibitors can affect patient quality of life and lead to treatment adjustments, including dose reduction or discontinuation. This retrospective study aimed to profile skin toxicities and their impact on treatment adjustments. A total of 288 non-small cell lung cancer patients treated with first-, second-, or third-generation epidermal growth factor receptor tyrosine kinase inhibitors were included. Skin toxicities, including papulopustular rash, xerosis, paronychia, and pruritus, were assessed based on medical records, and their severity was evaluated based on the required dermatological intervention. Papulopustular rash was the most common toxicity (74.3%), followed by pruritus (61.1%), xerosis (52.4%), and paronychia (39.6%). Papulopustular rash was more common in males and more severe in younger patients. Papulopustular rash was more prevalent in patients treated with first- and second-generation epidermal growth factor receptor tyrosine kinase inhibitors, while paronychia was notably frequent for the second-generation epidermal growth factor receptor tyrosine kinase inhibitors. Second-generation epidermal growth factor receptor tyrosine kinase inhibitors frequently caused multiple skin toxicities. Importantly, skin toxicities led to epidermal growth factor receptor tyrosine kinase inhibitor treatment adjustments in 26.7% of cases, with second-generation epidermal growth factor receptor tyrosine kinase inhibitors demonstrating higher adjustment rates. Papulopustular rash and paronychia were the main causes of treatment adjustments, with even mild paronychia being linked to treatment adjustments. Effective management of skin toxicities is essential for optimizing treatment outcomes in patients receiving epidermal growth factor receptor tyrosine kinase inhibitors.
Downloads
References
Sun W, Li J. Skin toxicities with epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients: a meta-analysis of randomized controlled trials. Cancer Invest 2019; 37: 253-264.
https://doi.org/10.1080/07357907.2019.1634089 DOI: https://doi.org/10.1080/07357907.2019.1634089
Segaert S, Van Cutsem E. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol 2005; 16: 1425-1433.
https://doi.org/10.1093/annonc/mdi279 DOI: https://doi.org/10.1093/annonc/mdi279
Li Y, Fu R, Jiang T, Duan D, Wu Y, Li C, et al. Mechanism of lethal skin toxicities induced by epidermal growth factor receptor inhibitors and related treatment strategies. Front Oncol 2022; 12: 804212.
https://doi.org/10.3389/fonc.2022.804212 DOI: https://doi.org/10.3389/fonc.2022.804212
Joly-Tonetti N, Ondet T, Monshouwer M, Stamatas GN. EGFR inhibitors switch keratinocytes from a proliferative to a differentiative phenotype affecting epidermal development and barrier function. BMC Cancer 2021; 21: 5.
https://doi.org/10.1186/s12885-020-07685-5 DOI: https://doi.org/10.1186/s12885-020-07685-5
Annunziata MC, De Stefano A, Fabbrocini G, Leo S, Marchetti P, Romano MC, et al. Current recommendations and novel strategies for the management of skin toxicities related to anti-EGFR therapies in patients with metastatic colorectal cancer. Clin Drug Investig 2019; 39: 825-834.
https://doi.org/10.1007/s40261-019-00811-7 DOI: https://doi.org/10.1007/s40261-019-00811-7
Jost M, Kari C, Rodeck U. The EGF receptor - an essential regulator of multiple epidermal functions. Eur J Dermatol 2000; 10: 505-510.
Mitchell EP, Perez-Soler R, Van Cutsem E, Lacouture ME. Clinical presentation and pathophysiology of EGFRI dermatologic toxicities. Oncology (Williston Park, NY), 2007; 21: 4-9.
Chan A, Delaloge S, Holmes FA, Moy B, Iwata H, Harvey VJ, et al. Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2016; 17: 367-377.
https://doi.org/10.1016/S1470-2045(15)00551-3 DOI: https://doi.org/10.1016/S1470-2045(15)00551-3
Abourehab MAS, Alqahtani AM, Youssif BGM, Gouda AM. Globally approved EGFR inhibitors: insights into their syntheses, target kinases, biological activities, receptor interactions, and metabolism. Molecules (Basel, Switzerland), 2021; 26.
https://doi.org/10.3390/molecules26216677 DOI: https://doi.org/10.3390/molecules26216677
He J, Huang Z, Han L, Gong Y, Xie C. Mechanisms and management of 3rd‑generation EGFR‑TKI resistance in advanced non‑small cell lung cancer (Review). Int J Oncol 2021; 59: 90.
https://doi.org/10.3892/ijo.2021.5270 DOI: https://doi.org/10.3892/ijo.2021.5270
Westover D, Zugazagoitia J, Cho BC, Lovly CM, Paz-Ares L. Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors. Ann Oncol 2018; 29: i10-i19.
https://doi.org/10.1093/annonc/mdx703 DOI: https://doi.org/10.1093/annonc/mdx703
Macdonald JB, Macdonald B, Golitz LE, LoRusso P, Sekulic A. Cutaneous adverse effects of targeted therapies, Part I: Inhibitors of the cellular membrane. J Am Acad Dermatol 2015; 72: 203-218; quiz 219-220.
https://doi.org/10.1016/j.jaad.2014.07.032 DOI: https://doi.org/10.1016/j.jaad.2014.07.032
Chu CY, Choi J, Eaby-Sandy B, Langer CJ, Lacouture ME. Osimertinib: a novel dermatologic adverse event profile in patients with lung cancer. Oncologist 2018; 23: 891-899.
https://doi.org/10.1634/theoncologist.2017-0582 DOI: https://doi.org/10.1634/theoncologist.2017-0582
Institute NC. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. Washington, DC: US Department of Health and Human Services, 2017.
Chu C-Y, Chen K-Y, Wen-Cheng Chang J, Wei Y-F, Lee C-H, Wang W-M. Taiwanese Dermatological Association consensus for the prevention and management of epidermal growth factor receptor tyrosine kinase inhibitor-related skin toxicities. J Formos Med Assoc 2017; 116: 413-423.
https://doi.org/10.1016/j.jfma.2017.03.001 DOI: https://doi.org/10.1016/j.jfma.2017.03.001
Zhao Y, Cheng B, Chen Z, Li J, Liang H, Chen Y, et al. Toxicity profile of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung cancer: a systematic review and network meta-analysis. Crit Rev Oncol Hematol 2021; 160: 103305.
https://doi.org/10.1016/j.critrevonc.2021.103305 DOI: https://doi.org/10.1016/j.critrevonc.2021.103305
Chan A, Tan EH. How well does the MESTT correlate with CTCAE scale for the grading of dermatological toxicities associated with oral tyrosine kinase inhibitors? Supportive Care Cancer 2011; 19: 1667-1674.
https://doi.org/10.1007/s00520-010-0999-2 DOI: https://doi.org/10.1007/s00520-010-0999-2
Wollenberg A, Moosmann N, Klein E, Katzer K. A tool for scoring of acneiform skin eruptions induced by EGF receptor inhibition. Exp Dermatol 2008; 17: 790-792.
https://doi.org/10.1111/j.1600-0625.2008.00715.x DOI: https://doi.org/10.1111/j.1600-0625.2008.00715.x
Beech J, Germetaki T, Judge M, Paton N, Collins J, Garbutt A, et al. Management and grading of EGFR inhibitor-induced cutaneous toxicity. Future Oncol 2018; 14: 2531-2541.
https://doi.org/10.2217/fon-2018-0187
Le-Rademacher JG, Rowland K, Atherton PJ, Dakhil C, Sun Z, Tan A, et al. Androgen mediation - and antiandrogens mitigation - of the epidermal growth factor receptor (EGFR) inhibitor-induced rash: results from a pilot randomized trial and small translational case series. Am J Hosp Palliat Care 2019; 36: 519-525.
https://doi.org/10.1177/1049909118819820 DOI: https://doi.org/10.1177/1049909118819820
Nakahara T, Moroi Y, Takayama K, Itoh E, Kido-Nakahara M, Nakanishi Y, et al. Changes in sebum levels and the development of acneiform rash in patients with non-small cell lung cancer after treatment with EGFR inhibitors. Onco Targets Ther 2015; 8: 259-263.
https://doi.org/10.2147/OTT.S76860 DOI: https://doi.org/10.2147/OTT.S76860
Reenstra WR, Yaar M, Gilchrest BA. Aging affects epidermal growth factor receptor phosphorylation and traffic kinetics. Exp Cell Res 1996; 227: 252-255.
https://doi.org/10.1006/excr.1996.0274 DOI: https://doi.org/10.1006/excr.1996.0274
Jatoi A, Green EM, Rowland KM, Jr., Sargent DJ, Alberts SR. Clinical predictors of severe cetuximab-induced rash: observations from 933 patients enrolled in north central cancer treatment group study N0147. Oncology 2009; 77: 120-123.
https://doi.org/10.1159/000229751 DOI: https://doi.org/10.1159/000229751
Beech J, Germetaki T, Judge M, Paton N, Collins J, Garbutt A, et al. Management and grading of EGFR inhibitor-induced cutaneous toxicity. Future Oncology 2018; 14: 2531-2541.
https://doi.org/10.2217/fon-2018-0187 DOI: https://doi.org/10.2217/fon-2018-0187
Finlay MRV, Anderton M, Ashton S, Ballard P, Bethel PA, Box MR, et al. Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor. J Med Chem, 2014; 57: 8249-8267.
https://doi.org/10.1021/jm500973a DOI: https://doi.org/10.1021/jm500973a
Russo A, Franchina T, Ricciardi GRR, Smiroldo V, Picciotto M, Zanghì M, et al. Third generation EGFR TKIs in EGFR-mutated NSCLC: where are we now and where are we going. Crit Rev Oncol Hematol 2017; 117: 38-47.
https://doi.org/10.1016/j.critrevonc.2017.07.003 DOI: https://doi.org/10.1016/j.critrevonc.2017.07.003
Shah DR, Shah RR, Morganroth J. Tyrosine kinase inhibitors: their on-target toxicities as potential indicators of efficacy. Drug Safety 2013; 36: 413-426.
https://doi.org/10.1007/s40264-013-0050-x DOI: https://doi.org/10.1007/s40264-013-0050-x
Bollinger MK, Agnew AS, Mascara GP. Osimertinib: a third-generation tyrosine kinase inhibitor for treatment of epidermal growth factor receptor-mutated non-small cell lung cancer with the acquired Thr790Met mutation. J Oncol Pharm Pract 2018; 24: 379-388.
https://doi.org/10.1177/1078155217712401 DOI: https://doi.org/10.1177/1078155217712401
Chen P, Chen F, Lei J, Zhou B. Curative effectiveness and safety of osimertinib in the treatment for non-small-cell lung cancer: a meta-analysis of the experimental evidence. Onco Targets Ther 2018; 11: 9033-9047.
https://doi.org/10.2147/OTT.S182077 DOI: https://doi.org/10.2147/OTT.S182077
Additional Files
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2024 Ji Su Lee, Jimin Woo, Tae Min Kim, Namkyu Kim, Bhumsuk Keam, Seong Jin Jo
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
